

Humber Area Prescribing Committee

Date / Time	3 rd April 2024 13:00-15:00
Venue	MS Teams
Chair	Dr Sergio Raise
Notes / Action Points	Luke Storr – Senior Pharmacy Technician, HUTH
Quorate: Yes / No	No – JM to send items to NP outside the meeting

Attendance	Dr Sergio Raise, ERY CCG GP Prescribing Lead (SR) Jane Morgan, Principal Pharmacist - Formulary, Interface and Medicines Commissioning, HUTH (JM) Luke Storr – Senior Pharmacy Technician, HUTH (LS) Andrew Karvot – Advanced Clinical and Northern Lincolnshire Interface Pharmacist, NLAG (AK) Simon Priestley- Chief Pharmacist, NLAG (SP) Laura Bulmer, Pharmacy Technician Project Manager, NECS (LB) Kevin McCorry, Medicines Optimisation Pharmacist, NECS (KMc) Daniel Newsome- Principal Pharmacist RDTC (DN) Caroline Hayward- Professional Development Pharmacist, Humber Local Pharmaceutical Committee (CH) Joanne Goode – Chief Pharmacist – HUTH (JG) Dr Rolan Schreiber, Medical Secretary LMC (RSc) Laura Angus- Chief Pharmacy Officer/ Director of Pharmacy and Medicines Optimisation- NHS Humber and North Yorkshire ICB (LA) Natasha Suffill- Lead Clinical Pharmacist CHCP (NS) Prof A Morice, Professor of Respiratory Medicine HUTH- (AM) Catherine Smith- Senior Medicines Optimisation Pharmacist, NECS Marian Opoku-Fofie – Deputy Chief Pharmacist – Humber Teaching NHS Foundation Trust (MOF)
Apologies	Narayana Pothina- Consultant in adult medicine, NLAG (NP) Manjeet Kaur-Deputy Chief Pharmacist, Rotherham, Doncaster and South Humber Foundation Trust (MK)

Agenda Number	Item	Discussion	Action	Lead	Due Date
2024.04.01	Apologies	Noted above			
2024.04.02	Declarations of interest	None			
2024.04.03	Minutes of previous meeting	Accepted as true record			
2024.04.04	Action Tracker	<p>Prescription requests in primary care –action transferred from NLAPC to Humber APC To produce joint document detailing supply details from secondary to primary care for all providers within Humber region To add links to relevant HUTH and NLAG guidance to website for information for primary care (discharge policies) June 2023: In progress July 2023: In progress August 2023: Received info from CHCP/HFT, JM to prepare new document. September 2023: In progress October 2023: In progress November 2023: In progress December 2023: In progress March 2024: In progress April 2024: Completed on this item</p> <p>Outstanding actions from NLAPC Funding for SCFs – mycophenolate, modafinil and riluzole (joint SCFs) JM to provide RS information on number of patients in NEL/NL December update: JM provided RS with patient numbers for mycophenolate, modafinil and riluzole February update: RS confirmed SCFs for modafinil and riluzole available within NEL; JM to upload SCFs (riluzole and modafinil for NEL). March update: SCFs uploaded onto Humber APC and linked into formulary. Awaiting NL – RS to update April update: Riluzole to JM to update websites to include NL May update: Riluzole updated, modafinil still waiting for NL, mycophenolate to review June update: Modafanil still waiting on NL, JM to review mycophenolate for July guideline group</p>	<p>Action complete</p> <p>Ongoing</p>	<p>AK/JM</p> <p>AK/JM</p>	<p>4/24</p> <p>7/24</p>

	<p>July update: JM to correct typo and send to RS, JM to review mycophenolate SCF for neurology for September guideline group</p> <p>August update: JM corrected typos, changed over on web and sent to RS, JM still to review mycophenolate SCF for September guideline group</p> <p>September 2023 update: For September guideline group</p> <p>October 2023 update: For November Guideline group</p> <p>November 2023 update: For November Guideline group</p> <p>December 2023 update: For January or March guideline group – to check against York mycophenolate.</p> <p>February 2024 update: reviewed against York SCF and contacted neuromuscular lead with national SCF. For March guideline group</p> <p>April 2024 update: RDTC have published reviewed and updated SCF. Neuromuscular lead happy with to update but to do as immunosuppression SCF for all places and specialities that use.</p> <p>Outstanding actions from HERPC</p> <p>Renal repatriation:</p> <p>November update – JM to meet with renal still; contacted business manager and clinical lead for renal medicine. To update further next time.</p> <p>December update – Not met with renal yet.</p> <p>March update – Updating business case.</p> <p>May update – to meet with NHSE</p> <p>August update – not yet met with NHSE</p> <p>September update: not yet met with NHSE</p> <p>October update: not yet met with NHSE</p> <p>November update: not yet met with NHSE</p> <p>December update: meeting arranged with NHSE</p> <p>February update: meeting arranged and business case in progress</p> <p>April 2024 update: JM and LA met with Paul McManus to discuss further.</p> <p>Blueteq</p> <p>Non-compliance to NICE guidance in acute trusts and financial impact</p> <p>June update: JM to submit ustekinumab report in gastroenterology HUTH when approved</p> <p>JM to present infliximab maintenance and initiation audits in gastroenterology HUTH when completed and approved</p>	Ongoing	JM	10/24
	<p>Blueteq</p> <p>Non-compliance to NICE guidance in acute trusts and financial impact</p> <p>June update: JM to submit ustekinumab report in gastroenterology HUTH when approved</p> <p>JM to present infliximab maintenance and initiation audits in gastroenterology HUTH when completed and approved</p>	Ongoing	JM	5/24

	<p>July update: JM to update next time.</p> <p>August update: no further update, infliximab audit in HUTH started</p> <p>September update: HUTH audits still ongoing</p> <p>October update: HUTH audits still ongoing</p> <p>November update: HUTH audits still ongoing</p> <p>December 2023 update: HUTH audits still ongoing, infliximab need more data and started adalimumab audit for homecare patients as recently done brand/provider switch.</p> <p>February 2024 update: Ustekinumab audit outcome form presented which demonstrated compliance with NICE guidance.</p> <p>March 2024 update: Infliximab paper due to presented at April D&TC</p> <p>April 2024 update: HUTH D&TC not until next week to update next time</p> <p>Outstanding actions from HERPC: Rheumatology to prepare pathway with rituximab without MTX</p> <p>August update: received NLAG pathway which includes this but not received HUTH pathway. Shared NLAG pathway with Dr Ogumbambi (rheumatology lead in HUTH). Rheumatology pathway for HUTH on D&TC action tracker. To discuss at September D&TC if Dr Ogumbambi in attendance and to contact to confirm place in pathway, to enable JM to start writing paper.</p> <p>September update: September D&TC next week, further updates to pathway needed</p> <p>October update: Awaiting updated pathway</p> <p>November update: Pathway needs further updates as new TAs published again and pharmacist who is updating has prioritised adalimumab switch.</p> <p>December update: ongoing</p> <p>February 2024 update: JG to follow up with Dr Ogumbambi</p> <p>March 2024 update: JG raised at HUTH D&TC; to bring NLAG RA pathway to next guideline group and invite Dr Alvi.</p> <p>April 2024 update: NLAG pathway on agenda.</p> <p>Ratification of guidelines and SCFs: Sick Day Guidance in T2DM</p> <p>JM to discuss with Matthew Heppel about printing this in colour/black and white and discuss with comms team</p> <p>December 2023 – ongoing</p> <p>February 2024 – ongoing</p>	Ongoing	JM	6/24
	<p>December 2023 – ongoing</p> <p>February 2024 – ongoing</p>	Ongoing	JM	6/24

	<p>April 2024 - ongoing</p> <p>Ratification of guidelines and SCFs: Amiodarone SCF JM to do minor updates and feedback to cardiology team at HUTH; check patient number for NEL/NL from NLAG/HUTH September 2023 update: JM fed back to cardiology team and updated. JM/AK to confirm patient numbers being dispensed at NLAG sites.</p> <p>October 2023 – RS fed back comments from NEL/NL GP leads. JM sent comments to cardiology team. JM confirmed patient numbers from outsourced outpatients at NLAG.</p> <p>November 2023 – to be discussed at next cardiology governance</p> <p>December 2023 - received comments from cardiology JM to review and send to RS/Catherine Smith after review</p> <p>February 2024 update: ongoing</p> <p>March 2024 update: JM to send updated SCF to CS for review.</p> <p>April 2024 update: ongoing</p>	Ongoing	JM	6/24
	<p>Feedback from Integrated Medicines Optimisation Committee</p> <p>Sodium valproate prevent compliance</p> <p>December 2023 –RS sent JM audit report and JM fed back to neurologists who state all their patients have annual review and forms.</p> <p>March 2024 update – ICB meetings with stakeholders underway. JM updating HUTH internal policy which will be shared with NLAG.</p> <p>April 2024 update – ICB meetings ongoing. JM meeting with HUTH team to look at internal improvements.</p>	Ongoing	JM/KMc	6/24
	<p>Ratification of guidelines and SCFs – JIC medication leaflet</p> <p>AK to send to St Andrews Hospice GP team.</p> <p>November update – contacted clinical directors and they were happy with content. Given a contact for logos and awaiting response</p> <p>December 2023 – Now have all logos and contact. JM to tidy up and publish on website.</p> <p>March 2024 – to publish on website</p> <p>April 2024 – action complete</p>	Action complete	AK/JM	4/24
	<p>Ratification of joint formulary – chapter 6</p> <p>To update netFormulary and remove HERPC chapter</p> <p>December update: ongoing</p> <p>March 2024 update: drugs all completed just links to update</p>	Action complete	JM/LS/AK	4/24

	<p>Work plans To add RDTSC SCF to guideline/SCF group to review against local SCFs when published April 2024 – work ongoing reviewing SCF workplan.</p> <p>Ratification of guidelines and SCFs To add information around initial supply of devices to erectile dysfunction following prostatectomy guidance</p> <p>Ratification of guidelines and SCFs To upload erectile dysfunction following prostatectomy to website and update formulary when uploaded</p> <p>RTDC updates To contact local services to discuss update of pathways and providing feedback to APC in timely manner. JM – to contact joint dermatology services hosted by HUTH (TA916), HUTH rheumatology (TA916/TA918/TA920), joint neurology services hosted by HUTH (TA919) and HUTH gastroenterology (TA925) JM to provide OA with HUTH IBD pathway to discuss with clinical lead. OA to contact NLAG gastroenterology(TA925) with HUTH pathway and NLAG rheumatology (TA916/TA918/TA920) March 2024 update: JM contacted dermatology, rheumatology and awaiting updated guidance, JM contacted neurology and updated guidance on agenda, JM contacted gastroenterology and TA925 already within APC approved pathway. OA contacted NLAG gastroenterology with HUTH guidance agreed to review guidance and aim for next version to be joint guidance. OA contacted NLAG rheumatology April 2024 update: Ongoing work with rheumatology and dermatology around PA pathways and ongoing with with gastro to look at merging guidance. JM met with Prof. Sebastian (IBD lead at HUTH) who is happy to liaise with NLAG as they develop their IBD service.</p> <p>Traffic Light Status To update Humber APC formulary -</p> <p>Traffic Light Status To update HERPC formulary where needed</p> <p>Ratification of guidelines and SCFs Upload relevant guidance/SCFs (orthostatic hypotension and NEL ADHD SCF)</p> <p>Ratification of guidelines and SCFs</p>	Ongoing	LS	6/24
		Ongoing	JM	4/24
		Ongoing	JM	4/24
		Ongoing	JM/OA	2/24
		Action complete	JM/AK/LS	4/24
		Action complete	JM/LS	4/24
		Action complete	JM	4/24
		Ongoing	JM/CS	4/24

		<p>JM to circulate issues with dementia SCFs for discussion outside of meeting and update next time</p> <p>April 2024 update: JM circulated documents, for NEL area dementia SCF is within current enhanced framework so agreed to use HERPC for the Parkinson's dementia patients seen by HUTH and NLAG. Agreed that until joint dementia SCF progressed HERPC SCF can be used in NL for both RDASH and HUTH. CS pursuing funding of HERPC SCF within NL</p> <p>Ratification of guidelines and SCFs</p> <p>LS to add heart failure guidance into papers for next meeting</p> <p>Ratification of joint formulary</p> <p>LS to add chapter 3 into papers for next meeting</p> <p>RTDC updates</p> <p>To update formulary/red list</p> <p>Any Other Business</p> <p>Fluticasone nasal sprays – to update formulary to note that fluticasone propionate is only for use when fluticasone furoate is out of stock and other alternatives are not suitable</p> <p>Any Other Business</p> <p>To update cyclizine to include injection use in palliative care when haloperidol not suitable</p>	Action complete	LS	4/24
			Action complete	LS	4/24
			Ongoing	JM	5/24
			Action complete	JM	4/24
			Action complete	JM	4/24
2024.04.05	Traffic Light Status	<p>Uromune- Proposed as RED- request feedback from anti-microbial group</p> <p>Fenfluramine- proposed as RED as per TA808 - formulary to reflect this and NHS England commissioning requirements</p> <p>Foslevodopa-foscarbidopa- proposed as RED as per TA934 – formulary to reflect this and NHS England commissioning requirements</p> <p>Belimumab- proposed as RED as per TA752 - formulary to reflect this and NHS England commissioning requirements</p> <p>Levomopromazine liquid- proposed as AMBER 1 with restriction for when 25mg tablet is unavailable or patients unable to take tablets</p>	Update formularies/red list Send uromune application to Susan Broughton	JM/LS/AK	
2024.04.06	Feedback from Integrated Medicines Optimisation Committee	<p>LB and LA presented</p> <ul style="list-style-type: none"> • Tirbanibulin has been pushed back to NYAPC for further information • Increase in Ferric Maltol prescription- anaemia guidance to be brought to HAPC when reviewed by acute trusts. • HST30 add to formulary in line with NHS England commissioning requirements (no providers in Y&H) • One system formulary responses (19 so far) has been positive 	Noted		

2024.04.07	Work plans	<ul style="list-style-type: none"> a) Joint formulary alignment b) Shared care frameworks c) Guidelines 	Ongoing for information only		
2024.04.08	Ratification of guidelines and SCFs	<ul style="list-style-type: none"> a) Quantities of medicines to be supplied – further information awaited from NAVIGO. Requires some standardisation of wording to make clearer. b) Glycopyrronium Amber guidance – currently hyoscine butylbromide injection has been in intermittent stock supply issue. This was a HERPC guidance that has been reviewed with minor updates and sent for consultation with the South Bank team. c) Sacubitril-Valsartan Amber guidance – this was guidance that was available for HERPC within the separate heart failure drug guidance which was removed however this section of the guidance was felt to be useful. Questions about the monitoring as drug classified as Amber 2 but monitoring being asked of primary care. d) NLaG Biologics in RA pathway – approved in line with TAs and addition of local rituximab without methotrexate e) Gonadorelin and Gondotrophin releasing hormone treatment of prostate cancer Amber guidance – Question raised around monitoring of therapy. JM to confirm with urology team. f) HF pathway – New pathway which shows the full patient journey not just drug usage however there is information on drug use that does not reflect NICE guidance. JM to contact Ben Davison to request that it does reflect NICE. 	<ul style="list-style-type: none"> a) Approved when standardised wording and b) approved- 3 years c) update monitoring d) Approved- ICB for costings e) Confirm with urology on monitoring f) To contact author 	JM	4/24
2024.04.09	Ratification of joint formulary	<ul style="list-style-type: none"> • Chapter 3 	Deferred to next meeting		
2024.04.10	RDTC updates	<ul style="list-style-type: none"> • Feb 24 • JM noted two 30 day TAs (TA956 which HUTH have updated IBD guideline to reflect and bring to next meeting and TA953 which is an update of two previous TAs and offers a cost and capacity saving versus using dexamethasone in this patient group 	Update formulary/red list	JM/LS/AK	4/24
2024.04.11	Minutes from subcommittees	<ul style="list-style-type: none"> a) Joint formulary subcommittee (Nil) b) Guideline subcommittee (Jan 2024) 	Attached for info only		
2024.04.12	Additional minutes for information	<ul style="list-style-type: none"> a) HUTH D&TC (Nil) b) HFT DTG (Jan 24) c) NLAG M&T (Nil) 	Attached for info only		

		d) NYY APC (Feb 24)			
2024.04.13	Correspondence received	Communication from memory clinic at Humber regarding practices refusing shared care received. SR raised that memory clinic are still sending out old version of SCF – SR to send any old versions to MOF outside meeting			
2024.04.14	AOB	<ul style="list-style-type: none"> AK raised classification of Nicorette quickmist which is being used by smoking cessation services in both HUTH and NLAG. To add to nicotine replacement products section with same purple section. 			
2024.04.15	Date of next meeting	1 st May 2024 13.00 – 15.00 Teams			